Cargando…
Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study
BACKGROUND: We designed this randomised, open-label, parallel group, multi-centre study to investigate the efficacy and safety of glycopyrronium/formoterol, a long-acting muscarinic antagonist/long-acting β2-agonist fixed dose combination, delivered through a dry powder inhaler (DPI) in patients wit...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623852/ https://www.ncbi.nlm.nih.gov/pubmed/36629200 http://dx.doi.org/10.4103/lungindia.lungindia_92_22 |
_version_ | 1784822098610356224 |
---|---|
author | Salvi, Sundeep Kumar, Anand Agrawal, Sumit Leuva, Amritlal Shukla, Vineet Kumar Deshpande, Shrikant Vishnu Balamurugan, Santhalingam Singh, Ajit Tikkiwal, Sharad Gupta, Sandeep K. Singh, Bhanu Pratap Lopez, Meena Sawant, Sandesh Vaidya, Abhijit Gogtay, Jaideep |
author_facet | Salvi, Sundeep Kumar, Anand Agrawal, Sumit Leuva, Amritlal Shukla, Vineet Kumar Deshpande, Shrikant Vishnu Balamurugan, Santhalingam Singh, Ajit Tikkiwal, Sharad Gupta, Sandeep K. Singh, Bhanu Pratap Lopez, Meena Sawant, Sandesh Vaidya, Abhijit Gogtay, Jaideep |
author_sort | Salvi, Sundeep |
collection | PubMed |
description | BACKGROUND: We designed this randomised, open-label, parallel group, multi-centre study to investigate the efficacy and safety of glycopyrronium/formoterol, a long-acting muscarinic antagonist/long-acting β2-agonist fixed dose combination, delivered through a dry powder inhaler (DPI) in patients with chronic obstructive pulmonary disease (COPD). MATERIAL AND METHODS: We randomised (1:1) patients with moderate to severe COPD (N = 356) to receive glycopyrronium 25 µg/formoterol 12 µg via DPI twice daily (GF-DPI) or glycopyrronium 50 µg monotherapy via DPI once daily (G-DPI). The primary study endpoint was the mean change from the baseline in pre-dose trough-forced expiratory volume in one second (FEV(1)) at 12 weeks. RESULTS: At week 12, the mean increase from the baseline in pre-dose trough FEV(1) was higher in the GF-DPI group (120 ml) than in the G-DPI (60 ml) group. The mean difference (MD) between treatment groups was 0.06 L (95% CI: 0.00–0.12 L, P < 0.0001 for non-inferiority). At week 12, the mean pre-dose forced vital capacity (FVC), 1 hour post-dose FEV(1), and post-dose FVC increased significantly from the baseline only in the GF-DPI group (p < 0.0001). The reduction in the COPD assessment test score was greater in the GF-DPI group (p = 0.0379). The average daily number of puffs of rescue medication and the reduction in mean modified Medical Research Council scale, COPD, and Asthma Sleep Impact Scale score at week 12 were similar between groups (p > 0.05). Overall, 35 adverse events and two serious adverse events unrelated to study drugs were reported. Both groups had similar results for overall drug safety. CONCLUSION: The results demonstrate efficacy and safety of GF-DPI in Indian patients with moderate to severe COPD. Treatment with GF-DPI significantly improved the lung function and quality of life and was well tolerated. |
format | Online Article Text |
id | pubmed-9623852 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-96238522022-11-02 Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study Salvi, Sundeep Kumar, Anand Agrawal, Sumit Leuva, Amritlal Shukla, Vineet Kumar Deshpande, Shrikant Vishnu Balamurugan, Santhalingam Singh, Ajit Tikkiwal, Sharad Gupta, Sandeep K. Singh, Bhanu Pratap Lopez, Meena Sawant, Sandesh Vaidya, Abhijit Gogtay, Jaideep Lung India Original Article BACKGROUND: We designed this randomised, open-label, parallel group, multi-centre study to investigate the efficacy and safety of glycopyrronium/formoterol, a long-acting muscarinic antagonist/long-acting β2-agonist fixed dose combination, delivered through a dry powder inhaler (DPI) in patients with chronic obstructive pulmonary disease (COPD). MATERIAL AND METHODS: We randomised (1:1) patients with moderate to severe COPD (N = 356) to receive glycopyrronium 25 µg/formoterol 12 µg via DPI twice daily (GF-DPI) or glycopyrronium 50 µg monotherapy via DPI once daily (G-DPI). The primary study endpoint was the mean change from the baseline in pre-dose trough-forced expiratory volume in one second (FEV(1)) at 12 weeks. RESULTS: At week 12, the mean increase from the baseline in pre-dose trough FEV(1) was higher in the GF-DPI group (120 ml) than in the G-DPI (60 ml) group. The mean difference (MD) between treatment groups was 0.06 L (95% CI: 0.00–0.12 L, P < 0.0001 for non-inferiority). At week 12, the mean pre-dose forced vital capacity (FVC), 1 hour post-dose FEV(1), and post-dose FVC increased significantly from the baseline only in the GF-DPI group (p < 0.0001). The reduction in the COPD assessment test score was greater in the GF-DPI group (p = 0.0379). The average daily number of puffs of rescue medication and the reduction in mean modified Medical Research Council scale, COPD, and Asthma Sleep Impact Scale score at week 12 were similar between groups (p > 0.05). Overall, 35 adverse events and two serious adverse events unrelated to study drugs were reported. Both groups had similar results for overall drug safety. CONCLUSION: The results demonstrate efficacy and safety of GF-DPI in Indian patients with moderate to severe COPD. Treatment with GF-DPI significantly improved the lung function and quality of life and was well tolerated. Wolters Kluwer - Medknow 2022 2022-08-29 /pmc/articles/PMC9623852/ /pubmed/36629200 http://dx.doi.org/10.4103/lungindia.lungindia_92_22 Text en Copyright: © 2022 Indian Chest Society https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Salvi, Sundeep Kumar, Anand Agrawal, Sumit Leuva, Amritlal Shukla, Vineet Kumar Deshpande, Shrikant Vishnu Balamurugan, Santhalingam Singh, Ajit Tikkiwal, Sharad Gupta, Sandeep K. Singh, Bhanu Pratap Lopez, Meena Sawant, Sandesh Vaidya, Abhijit Gogtay, Jaideep Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study |
title | Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study |
title_full | Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study |
title_fullStr | Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study |
title_full_unstemmed | Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study |
title_short | Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study |
title_sort | efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: results from a multi-centre, open-label, randomised study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623852/ https://www.ncbi.nlm.nih.gov/pubmed/36629200 http://dx.doi.org/10.4103/lungindia.lungindia_92_22 |
work_keys_str_mv | AT salvisundeep efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT kumaranand efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT agrawalsumit efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT leuvaamritlal efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT shuklavineetkumar efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT deshpandeshrikantvishnu efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT balamurugansanthalingam efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT singhajit efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT tikkiwalsharad efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT guptasandeepk efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT singhbhanupratap efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT lopezmeena efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT sawantsandesh efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT vaidyaabhijit efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy AT gogtayjaideep efficacyandsafetyofglycopyrroniumformoteroldeliveredviaadrypowderinhalerinpatientswithmoderatetoseverechronicobstructivepulmonarydiseaseresultsfromamulticentreopenlabelrandomisedstudy |